Cells fine-tune gene expression in response to cellular stress, a process critical for tumor progression that leads to cancer. However, elucidating mechanisms governing stress-responsive transcription remains an ongoing gap.  In a new study published in  …

Cancer P-glycoprotein (P-gp) is one of several ABC transporters that can pump drugs out of tumor cells and thereby render chemotherapy ineffective. Overexpression of P-gp can give rise to multidrug resistance, making cancers quite difficult to treat. …

… triple-negative breast cancer (TNBC) treated under an FDA-authorized … , chemotherapy, and antibody–drug conjugates. For example, pembrolizumab … July 2023 for the treatment of solid tumor … and planned confirmatory trial design for FDA discussion, Kazia’ …

… pill from Roche succeeded in a Phase 3 trial in early-stage breast cancer … therapy. So far, these drugs have largely only proven … drug called a CDK4/6 inhibitor, and allows treatment … ” the early treatment for ER-positive breast cancer “remains to be …

… breast cancer therapies? Needing a prior authorization for high-cost prescription medications … pharmacy services to support long-term physical and emotional recovery following breast cancer … ? There can be a lot beyond just the immediate treatment …

A new pill may slash the risk of deadly breast cancer returning after treatment, a … include medications to block the effects of estrogen.  The new drug binds … of the phase three lidERA Breast Cancer trial, which looked at 4,100 …

… the phase 3 VIKTORIA-1 trial (NCT05501886) in which the … advanced breast cancer who experienced disease progression during or following treatment with … end points of the trial were PFS by blinded … of its new drug application to the US FDA for gedatolisib …

… metastatic breast cancer represents a rapidly advancing treatment area, with novel ADCsantibody-drug conjugates … mechanistic rationale and early clinical trial outcomes. The experts discuss the …

… beating breast cancer. Amazonian scorpions could be the key to beating breast cancer Scientists … ’s Ribeirão Preto School of Pharmaceutical Sciences (FCFRP-USP) have pinpointed … the most widely used chemotherapy medications. The molecule triggers necrosis, a …

… trial results for giredestrant, a breast cancer treatment Olema is developing palazestrant, a similar drug … 1.28 million shares Olema Pharmaceuticals stock surged Tuesday morning … positive trial results suggest potential validation for this class of drugs. …